Close Menu

Cancer patients who received T cells engineered using the genome-editing technology CRISPR-Cas9 experienced no negative side effects from the treatment, according to a report in this week's Science. A team led by scientists from the University of Pennsylvania harvested T cells from three patients with refractory cancer, then used CRISPR-Cas9 to modify the cells in ways that improved their ability to target and fight tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.